

Diaceutics PLC - Results of AGM

New York, Belfast and London, 18 June 2025 - [Diaceutics PLC](#) (AIM: DXRX), a leading technology and solutions provider to the pharma and biotech industry, is pleased to announce that all resolutions proposed at its Annual General Meeting held earlier today, were duly passed. The proxy votes received from shareholders in respect of each resolution are set out below and are available on the Company's website www.diaceutics.com

Resolution	For (excluding at Chair's discretion)		Against		Total votes cast	Withheld	
	Number of votes	%	Number of votes	%	Number of votes	Number of votes	
1	Ordinary resolution to receive To receive and consider the Company's financial statements for the financial year ended 31 December 2024 together with the directors' report and the auditors' report on those annual accounts	54,937,420	99.99%	577	0.01%	54,937,997	Nil
2	Ordinary resolution to approve the directors' remuneration report	44,895,272	83.09%	9,136,725	16.91%	54,937,997	906,000
3	Ordinary resolution to re-elect Cheryl MacDiarmid as a director of the Company	54,937,420	99.99%	577	0.01%	54,937,997	Nil
4	Ordinary resolution to re-elect Jordan Clark as a director of the Company	51,811,362	99.98%	11,300	0.02%	54,937,997	3,115,335
5	Ordinary resolution to re-elect Nick Roberts as a director of the Company	51,639,642	99.65%	183,020	0.35%	54,937,997	3,115,335
6	Ordinary resolution to re-appoint Ernst & Young as auditors of the Company	54,925,512	99.98%	12,485	0.02%	54,937,997	Nil
7	Ordinary resolution to authorise the directors to determine the remuneration of the auditors	54,937,420	99.99%	577	0.01%	54,937,997	Nil
8	Ordinary resolution to authorise the directors to allot ordinary shares	54,905,822	99.94%	32,175	0.06%	54,937,997	Nil
9	Special resolution to authorise the directors to dis-apply statutory pre-emption rights pursuant to section 570 of the Companies Act 2006	53,670,136	99.92%	44,461	0.08%	54,937,997	1,223,400
10	Special resolution to authorise the directors to make market purchase of its ordinary shares	52,510,452	99.99%	577	0.01%	54,937,997	2,426,968
11	Ordinary resolution to approve The Diaceutics Unapproved Share Option Plan	51,312,153	93.40%	3,625,844	6.60%	54,937,997	Nil

Enquiries:
Diaceutics PLC

Ryan Keeling, Chief Executive Officer
Nick Roberts, Chief Financial Officer

Tel: +44 (0)28 9040 6500
investorrelations@diaceutics.com

Canaccord Genuity Limited (Nomad & Broker)

Simon Bridges, Andrew Potts, Harry Rees

Tel: +44 (0)20 7523 8000

About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to

positively impact their disease outcome. We provide the world's leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX - The Diagnostics Network®.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

RAGGPURCQUPAUBR